Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Recombinant Hepatitis B Vaccine Formulations in Healthy Adults
NCT00697125Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 1993
- Primary completion
- Jul 1994
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of hepatitis b vaccine recombinant in hepatitis B (HBV) (3 arms), sponsored by GSK. Primary endpoint: Occurrence and intensity of solicited local and general symptoms at 8 days. Started Jun 1993; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00697125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00697125.